The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The safety and efficacy of tirabrutinib and entospletinib with or without obinutuzumab in R/R CLL
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some results from a Phase II trial investigating the safety and efficacy of entospletinib and tirabrutinib with or without obinutuzumab for the treatment of patients with chronic lymphocytic leukemia (CLL). Unfortunately, this combination of agents did not result in higher rates of complete response or undetectable measurable residual disease (uMRD), and suggest that venetoclax-based combinations may be more effective for patients with CLL. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
